Our preliminary data suggest that patients with LUM B/HER2-/TK1+ BC undergoing adjuvant chemotherapy may require a longer and closer follow-up after surgery and/or a different adjuvant therapeutic algorithm. Here, ERBB2 is linked to breast cancer.